NL-OMON44369
Completed
Not Applicable
Clinical validation of a dried blood spot (DBS) method for the analysis of immunosuppressive and antifungal drugs in pediatric patients (part of the PROTECT study). - PROTECT
Afdeling Apotheek0 sites89 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- immuunsuppressie na niertransplantatie
- Sponsor
- Afdeling Apotheek
- Enrollment
- 89
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients aged between 2 and 18 years
- •Admitted to the pediatric ward or visiting the doctor on an outpatient basis
- •Having a venous catheter or blood is drawn for regular patient care
- •Treated with at least 1 of the 9 drugs of interest
- •Signed informed consent
Exclusion Criteria
- •Parents and/or patients are not able to understand the Dutch language
Outcomes
Primary Outcomes
Not specified
Similar Trials
Withdrawn
Not Applicable
Clinical validation of a dried blood spot (DBS) method for the analysis of rifampicin (RIBOD study).analysis of drugs used for tuberculosis10004018NL-OMON42070niversitair Medisch Centrum Sint Radboud10
Completed
Not Applicable
Clinical validation of the Dry Blood Spot (DBS) method for risperidone, aripiprazole, pipamperone and its major metabolitesnvt10013511NL-OMON45799Erasmus MC, Universitair Medisch Centrum Rotterdam120
Completed
Not Applicable
Clinical validation of the Dry Blood Spot (DBS) method for risperidone, aripiprazole, pipamperone and its major metabolitesantipsychotics, pipamperone, aripiprazole, paliperidone, risperidoneNL-OMON28955Erasmus MC Medical Center60
Completed
Not Applicable
Clinical validation of the dried blood spot analysis for antituberculosis drugsBlood concentration of anti TB drugs10028440NL-OMON34891niversitair Medisch Centrum Groningen33
Recruiting
Not Applicable
Clinical evaluation of dried blood spots for the determination of ribociclib blood levelsNL-OMON25336ovartis20